Through the most comprehensive integrated genetic study to date using 19 TFE3-positive RCC cases, we provide a genomic landscape and a deeper understanding of the oncogenic mechanism of tRCC, facilitating further discovery of a therapeutic strategy for tRCC. The gene discussed is TFE3; the disease is renal cell adenocarcinoma.